PL1635838T3 - Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego - Google Patents

Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego

Info

Publication number
PL1635838T3
PL1635838T3 PL04739573T PL04739573T PL1635838T3 PL 1635838 T3 PL1635838 T3 PL 1635838T3 PL 04739573 T PL04739573 T PL 04739573T PL 04739573 T PL04739573 T PL 04739573T PL 1635838 T3 PL1635838 T3 PL 1635838T3
Authority
PL
Poland
Prior art keywords
portal hypertension
portal
inhibitor
prevent
treat
Prior art date
Application number
PL04739573T
Other languages
English (en)
Inventor
Wolfgang Kreisel
Original Assignee
Univ Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Freiburg filed Critical Univ Freiburg
Publication of PL1635838T3 publication Critical patent/PL1635838T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04739573T 2003-06-06 2004-06-03 Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego PL1635838T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10325813A DE10325813B4 (de) 2003-06-06 2003-06-06 Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP04739573A EP1635838B1 (de) 2003-06-06 2004-06-03 Phosphodiesterase-5-inhibitoren zur prophylaxe und/oder therapie der portalen hypertonie
PCT/EP2004/006014 WO2004108062A2 (de) 2003-06-06 2004-06-03 Prophylaxe und/oder therapie bei der portalen hypertonie

Publications (1)

Publication Number Publication Date
PL1635838T3 true PL1635838T3 (pl) 2007-09-28

Family

ID=33494881

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06025229T PL1923073T3 (pl) 2003-06-06 2004-06-03 Leczenie kombinacyjne z inhibitorem PDE-5
PL04739573T PL1635838T3 (pl) 2003-06-06 2004-06-03 Inhibitory fosfodiesterazy -5 do zapobiegania i/lub leczenia nadciśnienia wrotnego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06025229T PL1923073T3 (pl) 2003-06-06 2004-06-03 Leczenie kombinacyjne z inhibitorem PDE-5

Country Status (14)

Country Link
US (1) US9278097B2 (pl)
EP (2) EP1635838B1 (pl)
JP (3) JP4557970B2 (pl)
KR (2) KR101233828B1 (pl)
CN (1) CN1871010B (pl)
AT (2) ATE361074T1 (pl)
CY (2) CY1107707T1 (pl)
DE (2) DE10325813B4 (pl)
DK (2) DK1923073T3 (pl)
ES (2) ES2287740T3 (pl)
PL (2) PL1923073T3 (pl)
PT (2) PT1635838E (pl)
SI (2) SI1923073T1 (pl)
WO (1) WO2004108062A2 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089808A1 (de) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
PT1888074E (pt) * 2005-06-10 2012-03-01 Dong A Pharm Co Ltd Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
US8512258B2 (en) * 2005-11-11 2013-08-20 Exalenz Bioscience Ltd. Breath test device and method
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
WO2014088326A1 (ko) 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US11576609B2 (en) 2017-06-30 2023-02-14 Georgia State University Research Foundation, Inc. Noninvasive methods for detecting liver fibrosis
CA3023014C (en) * 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
CN110811593A (zh) * 2019-11-07 2020-02-21 天津中医药大学第二附属医院 一种高血压中医证型采取肝血流动力学特点的判别方法
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2882843B2 (ja) * 1990-03-28 1999-04-12 日本化薬株式会社 門脈圧亢進症改善剤
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5973011A (en) * 1994-03-30 1999-10-26 Isis Pharma Gmbh Pharmaceutical preparations and medicaments for the prevention and treatment of endothelial dysfunction
IL144156A0 (en) 1999-01-20 2002-05-23 Dresden Arzneimittel Use of imidazo [1,5-a]-pyrido [3,2-e] -pyrazinones as medicaments
DE19961302A1 (de) * 1999-12-18 2001-06-21 Dresden Arzneimittel Verwendung von Imidazo(1,5-a)-pyrido(3,2-e)-pyrazinonen als duale Inhibitoren der Phosphodiesterase 5 und der Phosphodiesterase 3 zur Therapie der Herzinsuffizienz, von pulmonaler Hypertonie und Gefäßerkrankungen, die mit einer Minderdurchblutung einhergehen
AU3210500A (en) * 1999-01-22 2000-08-07 Selectus Pharmaceuticals, Inc. Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US20010003120A1 (en) * 1999-05-14 2001-06-07 M. D. Robert Hines Method for treating erectile dysfunction
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
TWI224966B (en) 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
US20020103117A1 (en) 2000-02-03 2002-08-01 Ralph Knoell Use of protein kinase-inhibitor-alpha
DE10004858A1 (de) * 2000-02-03 2001-08-16 Schering Ag Verwendung von Proteinkinase-Inhibitor-alpha
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
MXPA03001717A (es) 2000-08-30 2003-09-22 Lilly Icos Llc METODO PARA EL TRATAMIENTO DE LA MIGRAnA.
US20020028764A1 (en) * 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
CA2426674A1 (en) 2000-10-25 2002-05-02 Takeda Chemical Industries, Ltd. Agent for preventing or treating portal hypertension
JP2002201128A (ja) * 2000-10-25 2002-07-16 Takeda Chem Ind Ltd 門脈圧亢進症予防・治療剤
HUP0302987A2 (hu) * 2001-01-31 2003-12-29 Merck Patent Gmbh Pirazolo [4,3-d] pirimidinszármazékokat vagy tienopirimidinszármazékokat és nitrátvegyületeket tartalmazó gyógyászati készítmények
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
JP2004525890A (ja) 2001-02-02 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤
US6338862B1 (en) * 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
BR0210915A (pt) 2001-06-08 2004-06-08 Sod Conseils Rech Applic Análogos quiméricos de somatostatina-dopamina
LV12979B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition

Also Published As

Publication number Publication date
PL1923073T3 (pl) 2012-02-29
EP1923073B1 (de) 2011-09-21
DE10325813B4 (de) 2007-12-20
DE10325813A1 (de) 2005-01-05
KR20120024807A (ko) 2012-03-14
US20070004744A1 (en) 2007-01-04
WO2004108062A2 (de) 2004-12-16
JP2009280602A (ja) 2009-12-03
ES2374085T3 (es) 2012-02-13
DK1923073T3 (da) 2011-10-17
KR20060031614A (ko) 2006-04-12
SI1635838T1 (sl) 2007-10-31
EP1635838B1 (de) 2007-05-02
ES2287740T3 (es) 2007-12-16
EP1635838A2 (de) 2006-03-22
EP1923073A3 (de) 2008-07-09
CY1111918T1 (el) 2015-11-04
ATE361074T1 (de) 2007-05-15
CN1871010B (zh) 2010-05-26
SI1923073T1 (sl) 2011-11-30
KR101176110B1 (ko) 2012-08-22
DK1635838T3 (da) 2007-09-10
KR101233828B1 (ko) 2013-02-14
CY1107707T1 (el) 2013-04-18
JP2006527177A (ja) 2006-11-30
JP5631053B2 (ja) 2014-11-26
EP1923073A2 (de) 2008-05-21
US9278097B2 (en) 2016-03-08
JP2010195821A (ja) 2010-09-09
PT1635838E (pt) 2007-08-10
PT1923073E (pt) 2011-10-04
JP4557970B2 (ja) 2010-10-06
DE502004003694D1 (de) 2007-06-14
JP5757677B2 (ja) 2015-07-29
WO2004108062A3 (de) 2005-03-10
CN1871010A (zh) 2006-11-29
ATE525074T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
CY1107707T1 (el) Αναστολεις της φωσφοδιεστερασης-5 για την προφυλαξη και/ή τη θεραπεια της πυλαιας υπερτασης
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
WO2003035009A3 (en) Treatment of acute myeloid leukemia with indolinone compounds
NO20010844L (no) Regulering av substrataktivitet
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
IL160420A0 (en) Treating or preventing diabetes with cannabidiol
MXPA05003346A (es) Control glicemico mejorado para prediabetes y/o diabetes tipo ii utilizando acido docosahexaenoico.
AU2002351753A8 (en) Combined use of a glp-1 compound and a modulator of diabetic late complications
EP1500403A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
DE602007008385D1 (de) Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
NZ510920A (en) Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans
CA2339049A1 (en) Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
WO2002030867A3 (en) Drugs for diabetes
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
NO20000087L (no) Behandling av inflammatoriske sykdommer i tarmen og urinblære
EP2125021B8 (en) Combination therapy of lower urinary tract disorders with alpha 2delta ligands and nsaids
NZ519722A (en) Treatment of diabetic ulcers
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
AU2003223528A1 (en) Treatment for type 1 diabetes before and after expression of predisposition markers.
WO2003004046A3 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
NO20024545L (no) Fremgangsmåte for behandling av kongestiv hjertefeil